Galecto Inc (NAS:GLTO)
$ 0.6232 -0.0067 (-1.06%) Market Cap: 16.90 Mil Enterprise Value: -9.94 Mil PE Ratio: 0 PB Ratio: 0.60 GF Score: 38/100

Galecto Inc at HC Wainwright Investment Conference - New York Transcript

Sep 11, 2023 / 11:00AM GMT
Release Date Price: $0.57 (+1.42%)
Boobalan Pachaiyappan
H.C. Wainwright & Co., LLC - Analyst

Hello, everyone. My name is Boobalan Pachaiyappan. I'm H.C. Wainwright Vice President and senior biopharma analyst. With me today is Dr. Hans Schambye, Chief Executive Officer of Galecto.

For investors new to the story, Galecto is a clinical-stage biotech focused on developing novel drugs for fibrosis and cancers. Hans, welcome to the show.

Hans Schambye
Galecto, Inc. - CEO

Thanks a lot, Boobalan. Happy to be here.

Boobalan Pachaiyappan
H.C. Wainwright & Co., LLC - Analyst

Great. So before getting started, I would like to make a disclosure here. I cover Galecto with my colleague, Dr. Ram Selvaraju, who's the Managing Director at the firm. Our recommendation for Galecto is buy rating and $2 price target.

Questions & Answers

Boobalan Pachaiyappan
H.C. Wainwright & Co., LLC - Analyst

Hans, with the formalities out of the way, let's just begin our discussion with IPF program. So

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot